Hsp-based tumor vaccines: state-of-the-art and future directions.
Hsp-based tumor vaccines, autologous tumor-derived Hsp-peptide complexes, have been applied to cancer immunotherapy for the treatment of cancer patients with a variety of advanced malignancies. Data from clinical trials, including those from phase III, have so far demonstrated that the immunization strategy can induce significant tumor-specific immune responses. Some improved clinical outcomes have also been observed but the clinical utility of this strategy awaits further investigations. In addition, preclinical studies have been conducted to design a variety of novel Hsp-based tumor vaccines with improved therapeutic potentials. These approaches include development of Hsp fusion proteins and genetic vaccines using plasmid DNA and adenoviruses. Successful cancer immunotherapy with Hsp-based tumor vaccines will depend on the results obtained from both clinical trials and preclinical studies.
Takakura
Yoshinobu
Y
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. takakura@pharm.kyoto-u.ac.jp
Takemoto
Seiji
S
Nishikawa
Makiya
M
D000256:Adenoviridae / Q000235:genetics / Q000378:metabolism; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D016233:Immunotherapy, Active / Q000639:trends*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000627:therapeutic use; D019444:Vaccines, DNA / Q000627:therapeutic use
D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA